Updated Statement: Bristol Myers Squibb on Coronavirus (COVID-19)

Release Date: Wednesday, May 13, 2020 4:30 pm EDT

Terms: Corporate/Financial News

Dateline City: PRINCETON, N.J.

Throughout the unprecedented and evolving COVID-19 pandemic, Bristol Myers Squibb has focused on protecting the health and safety of our workforce, ensuring the continued supply of our medicines to our patients and supporting relief efforts across the globe.

Workplace and Community

- In March, we required our global workforce that is able to work from home to do so and suspended in-person interactions by our customer-facing (field) personnel in healthcare settings in the U.S. and certain other markets. Direction from local health and government authorities on this matter has taken precedence in certain markets.
- As we advance planning efforts to bring our remote workforce back to our 250+ sites around the world and into the field, we are being guided by the following principles:
  - Serving the Needs of our Patients and Customers
  - Prioritizing Health and Safety
  - Following Medical Advice and Government Direction
  - Leading with Compassion and Flexibility
  - Modeling Key Learnings
- No single approach will fit for every site or market. While timelines and circumstances will vary across the globe, across our enterprise, we will take a thoughtful and phased approach. We have a number of sites, including in China, South Korea, Taiwan, and Israel that have already begun this process.
- We will continue to take significant measures to protect the safety of our colleagues on site, including providing protective equipment, ensuring physical distancing and enhancing cleaning.
- We will maintain our restrictions on business travel, visitor access, workplace and in-person meetings. These restrictions apply to all Bristol Myers Squibb employees, business partners, contractors, suppliers and vendors.

Supply of Our Medicines

- An important element of keeping our promise to patients, their families and our healthcare providers is to ensure that our supply chain continues to deliver our medicines without interruption.
- Our clinical and commercial supply chain teams have proactively booked alternative means for moving our raw materials and products to our markets and clinical sites over the past months. Thanks to these efforts, we have not seen any disruption in our clinical or commercial supply chain due to the pandemic.

Our Clinical Trials and Research

- We are working with health authorities and investigators to protect our trial participants and personnel at Bristol Myers Squibb and our clinical trial sites, while ensuring regulatory compliance and the integrity of our science.
- We have provided clinical trial investigators with overarching principles and guidance regarding the conduct of BMS clinical trials worldwide in light of COVID-19, and are taking into account guidance from health authorities, where applicable.
- In some instances, we are continuing clinical studies as planned, while in others we are temporarily suspending or postponing trials as appropriate. For trials which were suspended or postponed, plans are underway to get them back up and running when circumstances on the ground permit.

Global Relief Efforts

- Bristol Myers Squibb and the Bristol Myers Squibb Foundation, a 501(c)(3) organization, are actively and separately contributing to relief efforts around the world. Together, Bristol Myers Squibb and the Bristol Myers Squibb Foundation have contributed more than $22 million in financial support and needed products (e.g. PPE and medical equipment) to relief efforts in 40 countries. We’re focusing on areas of highest unmet need, including ensuring basic human needs, addressing medical supply shortages and supporting continued care of our most vulnerable communities.
- The Bristol Myers Squibb Foundation has supported nearly 50 organizations in the U.S. that provide critical aid and more than 150 organizations across Africa, Asia, Europe, North America and South America that ensure basic human needs and enable continued patient care, along with global organizations supporting those on the frontlines of the COVID-19 response.
- The Bristol Myers Squibb Foundation has contributed to more than 40 patient advocacy groups and professional societies on the frontlines of patient care, and Bristol Myers Squibb is engaging with more than 250 patient and professional organizations to support research, education, patient psychosocial support and basic human needs.
- Notable examples include:
  - A $7 million grant from the Bristol Myers Squibb Foundation to Team Rubicon’s and Patient Advocate Foundation’s
COVID-19 Emergency Food Assistance Program, which is providing assistance to immunocompromised patients living with cancer, multiple sclerosis or rheumatoid arthritis whose ability to access or afford food and other nutritional needs is at risk due to the COVID-19 pandemic.

- **Bristol Myers Squibb’s partnership with GRYT Health to develop the COVID Advocacy Exchange**, a virtual platform to unite patient advocacy organizations, patients, policy makers, healthcare practitioners and industry in the exchange of information.

- We are supporting our colleagues across the world who are volunteering on the frontlines and virtually in the fight against COVID-19. Colleagues who are licensed healthcare professionals who choose to volunteer in local hospitals continue to receive pay. Through Skills2Give, an ongoing Bristol Myers Squibb volunteer program, colleagues in the U.S., U.K. and Australia have the option to select from virtual volunteer opportunities with thousands of nonprofit organizations. Over 3,000 employees are registered with the program.

**Contributions to Research, Life-Sciences Industry**

- We are working with researchers, the biotech community and the broader life sciences industry on ways we together can accelerate therapies for COVID-19.
- Among other efforts, we have identified approximately 1,000 compounds in our discovery library that we’re making available to collaborators for screening for potential molecules to treat COVID-19.
- We are evaluating certain medicines in our portfolio that could be included in near-term clinical trials with a focus on agents that may have an impact on the inflammatory immune response associated with COVID-19. This research may advance as either company-sponsored or investigator-sponsored trials under the leadership of a cross-functional team focused on advancing this science with a sense of urgency.
- We are also participating in several cross-industry groups and public-private partnerships designed to foster collaboration and coordinate industry response efforts, and thereby accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19.

We are grateful to the healthcare professionals on the frontlines who are fighting to help patients with COVID-19. We are thankful to our more than 30,000 colleagues who have never stopped working for patients, have demonstrated incredible resolve and support for one another, and have contributed meaningfully to global relief efforts.

As a responsible global citizen, we will take all necessary actions to promote public health and carry out our mission of providing life-saving medicines to the patients who depend on us.

For further inquiries, please contact media@bms.com.

**Language:**

English